Martha Louzada
Overview
Explore the profile of Martha Louzada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
110
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tanguay M, Roy J, Su J, Gul E, Reece D, Venner C, et al.
Cancer Med
. 2024 Nov;
13(21):e70332.
PMID: 39499045
Background: Young patients ≤ 50 years old with multiple myeloma (MM) account for about 10% of cases and are underrepresented in the literature. Methods: We explored disease characteristics, treatments, and...
2.
Venner C, Duggan P, Song K, Reece D, Sharma S, Su J, et al.
Transplant Cell Ther
. 2024 Jul;
30(9):889-901.
PMID: 38971462
In patients with multiple myeloma (MM), the presence of high-risk cytogenetic abnormalities is associated with worse disease control and survival. Autologous stem cell transplant (ASCT) does benefit these patients. Tandem...
3.
Kaedbey R, Reece D, Venner C, McCurdy A, Su J, Chu M, et al.
EJHaem
. 2024 Jun;
5(3):474-484.
PMID: 38895063
Multiple myeloma remains an incurable cancer mostly affecting older adults and is characterized by a series of remission inductions and relapses. This study aims to evaluate the outcomes in newly...
4.
Haider I, Leong D, Louzada M, McCurdy A, Pond G, Cameron R, et al.
Leuk Lymphoma
. 2024 Apr;
65(8):1167-1174.
PMID: 38625039
There is limited knowledge regarding the prevalence of geriatric impairments and frailty among patients with multiple myeloma (MM) in a real-world setting. This study evaluated the distribution of frailty profiles...
5.
Hillyer A, Quint A, Ghassemian A, Joh-Carnella N, Knauer M, Dawd D, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Feb;
24(5):305-315.
PMID: 38336492
Background: Patients with hematological cancers have increased COVID-19 morbidity and mortality, and these patients show attenuated vaccine responses. This study aimed to characterize the longitudinal humoral immune responses to COVID-19...
6.
Cote J, LeBlanc R, Mian H, Chu M, McCurdy A, Masih-Khan E, et al.
Blood Cancer J
. 2023 Sep;
13(1):137.
PMID: 37669949
Autologous stem cell transplant (ASCT) remains an important option for eligible multiple myeloma (MM) patients as part of initial therapy. Using the Canadian Myeloma Research Group (CMRG) national database, we...
7.
McCurdy A, Mian H, LeBlanc R, Jimenez-Zepeda V, Su J, Masih-Khan E, et al.
Blood Cancer J
. 2023 Aug;
13(1):129.
PMID: 37635183
No abstract available.
8.
LeBlanc R, Mian H, Reece D, Su J, Masih-Khan E, Chu M, et al.
Eur J Haematol
. 2023 Aug;
111(5):815-823.
PMID: 37574220
Introduction: Although daratumumab-containing regimens improve multiple myeloma (MM) outcomes, recurrence is inevitable. Methods And Objective: We performed a retrospective study using the Canadian Myeloma Research Group Database to benchmark the...
9.
McCurdy A, Mian H, LeBlanc R, Jimenez-Zepeda V, Su J, Masih-Khan E, et al.
Blood Cancer J
. 2023 Jul;
13(1):111.
PMID: 37474492
While most patients diagnosed with multiple myeloma (MM) receive initial therapy, reported attrition rates are high. Understanding attrition rates and characteristics of patients not receiving subsequent therapy is useful for...
10.
McCurdy A, Louzada M, Venner C, Visram A, Masih-Khan E, Kardjadj M, et al.
EJHaem
. 2022 Dec;
3(4):1252-1261.
PMID: 36467802
Carfilzomib is an active and commonly used treatment in patients with multiple myeloma (MM). Using the Canadian Myeloma Research Group Database, we performed a retrospective observational study of patients treated...